Monika Kadian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Monika Kadian has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Kajal Joshi
Himachal Institute of Pharmaceutical Education & Research, Nadaun-177033 (Himachal Pradesh), India
1 shared publication - Kalpana Nagpal
Amity Institute of Pharmacy, Amity University, Noida, India
1 shared publication - Mini Dahiya
University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies (UGC-CAS), Panjab University, Chandigarh 160014, India
1 shared publication - Monu Yadav
Amity Institute of Pharmacy, Amity University Haryana, Gurugram, 122413, India
1 shared publication - Nidhi Sharma
D.J. College of Pharmacy, Modinagar, 201204, Uttar Pradesh, India
1 shared publication
Latest Publications
- 16 October 2020
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 16, 1-19
Emerging Biomarkers and Contributing Factors of Prostate Cancer.
: Prostate Cancer (PC) is one the most prominent cause of deaths in males worldwide especially in western countries. The exhaustive research into prostate cancer to date has demonstrated ELAC2, RNASEL, MSR1, NBS1, CHEK2, MYC, BCL-2, c-Kit, tumor suppressor genes, BRCA1, BRCA2, PACE4, GSTP1, PTEN,CDKN1B, NKX3.1, KLF6, FOXA1, Retinoblastoma, p53, androgen receptor, kallikreins, ETS, CYP17, SRD5A2, E-cadherin, KAI1/CD82, hepsin, AMACR, PIM1, MTA-1, EZH2, EPHB2, growth factors & its receptors, cannabinoid receptors, annexins, oxidative stress and inflammation are entailed changes underlying the initiation, development, and progression of PC. Furthermore, oncology would shift from a reactive to proactive discipline so exploring these targets open new area of research. Therefore, the present review is focused on molecular pathophysiology biomarkers for the progression of PC that would encourage the researchers and pharmaceutical industries to investigate potential therapeutic strategy to overcome demerits of currently available clinically therapies.
- 16 October 2020
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 16, 1-19
Emerging Biomarkers and Contributing Factors of Prostate Cancer.
: Prostate Cancer (PC) is one the most prominent cause of deaths in males worldwide especially in western countries. The exhaustive research into prostate cancer to date has demonstrated ELAC2, RNASEL, MSR1, NBS1, CHEK2, MYC, BCL-2, c-Kit, tumor suppressor genes, BRCA1, BRCA2, PACE4, GSTP1, PTEN,CDKN1B, NKX3.1, KLF6, FOXA1, Retinoblastoma, p53, androgen receptor, kallikreins, ETS, CYP17, SRD5A2, E-cadherin, KAI1/CD82, hepsin, AMACR, PIM1, MTA-1, EZH2, EPHB2, growth factors & its receptors, cannabinoid receptors, annexins, oxidative stress and inflammation are entailed changes underlying the initiation, development, and progression of PC. Furthermore, oncology would shift from a reactive to proactive discipline so exploring these targets open new area of research. Therefore, the present review is focused on molecular pathophysiology biomarkers for the progression of PC that would encourage the researchers and pharmaceutical industries to investigate potential therapeutic strategy to overcome demerits of currently available clinically therapies.